Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + trastuzumab

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin (Adriamycin), and trastuzumab (Herceptin). Cyclophosphamide is an alkylating agent that damages DNA during the cell's resting phase. Doxorubicin is an anthracycline antibiotic that damages DNA at any point in the cell cycle. Trastuzumab is a monoclonal antibody that targets the HER2 protein found in high amounts in some breast cancers. This combination is primarily used for HER2-positive breast cancer treatment.

Other names: AC-T with trastuzumabAC-Herceptin

Targets

TOP2A (DNA topoisomerase II)DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + trastuzumab.

Explore the full profile